All In Biotech

Drug Trial Radar · NCT03487276

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Feb 26, 2018

Primary completion

May 27, 2019

Study completion Jan 27, 2020

Sponsor

Lead sponsor
InflaRx GmbHIndustry
Sponsor type
Industry
Collaborators
Quintiles, Inc.
First posted
Apr 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • IFX-1Drug

    Single IV infusions of IFX-1 diluted in sodium chloride.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16Time frame: Week 16

Locations

41 sites in 9 countries. Site status is shown where the registry gives one.

  • InflaRX Investigational Site

    Birmingham, Alabama

  • InflaRX Investigational Site

    Fort Myers, Florida

  • InflaRX Investigational Site

    Miami, Florida

  • InflaRX Investigational Site

    Sandy Springs, Georgia

  • InflaRX Investigational Site

    Dearborn, Michigan

  • InflaRX Investigational Site

    Columbia, Missouri

  • InflaRx Investigational Site

    Saint Joseph, Missouri

  • InflaRX Investigational Site

    St Louis, Missouri

  • InflaRX Investigational Site

    St Louis, Missouri

  • InflaRX Investigational Site

    Chapel Hill, North Carolina

  • InflaRX Investigational Site

    Cincinnati, Ohio

  • InflaRX Investigational Site

    Hershey, Pennsylvania

  • InflaRx Investigational Site

    Goodlettsville, Tennessee

  • InflaRX Investigational Site

    Sofia, Bulgaria

  • InflaRX Investigational Site

    Sofia, Bulgaria

  • InflaRX Investigational Site

    Stara Zagora, Bulgaria

  • InflaRX Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • InflaRX Investigational Site

    Peterborough, Ontario, Canada

  • InflaRX Investigational Site

    Richmond Hill, Ontario, Canada

  • InflaRX Investigational Site

    Copenhagen, Denmark

  • InflaRX Investigational Site

    Roskilde, Denmark

  • InflaRX Investigational Site

    Paris, France

  • InflaRX Investigational Site

    Nice, Alpes Maritimes, France

  • InflaRX Investigational Site

    Bordeaux, Gironde, France

  • InflaRX Investigational Site

    Toulouse, Haute Garonne, France

  • InflaRX Investigational Site

    Antony, Hauts De Seine, France

  • InflaRX Investigational Site

    Nantes, Loire Atlantique, France

  • InflaRX Investigational Site

    Darmstadt, Hesse, Germany

  • InflaRX Investigational Site

    Frankfurt am Main, Hesse, Germany

  • InflaRX Investigational Site

    Bochum, North Rhine-Westphalia, Germany

  • InflaRX Investigational Site

    Dessau, Saxony-Anhalt, Germany

  • InflaRX Investigational Site

    Athens, Greece

  • InflaRX Investigational Site

    Athens, Greece

  • InflaRX Investigational Site

    Thessaloniki, Greece

  • InflaRX Investigational Site

    Rotterdam, Netherlands

  • InflaRX Investigational Site

    Gdansk, Poland

  • InflaRX Investigational Site

    Kłodzko, Poland

  • InflaRX Investigational Site

    Krakow, Poland

  • InflaRX Investigational Site

    Lodz, Poland

  • InflaRX Investigational Site

    Wroclaw, Poland

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.